[Serological surveillance on vaccine against hemorrhagic fever with renal syndrome].
OBJECTIVE
To observe the serological and epidemiological efficacy of hemorrhagic fever renal syndrome (HFRS) vaccine in Zhejiang province.


METHODS
Immunofluorescent antibody assay and Mcro-CPE method were used to test specific IgG antibody and the titer of neutralizing antibody.


RESULTS
Two weeks after the injection of the third dose, the sero-conversion rates by both immunofluorescent antibody test (IgG) and neutralization test were 100.0% (67/67) (95% CI: 96.3 - 100.0) and 44.4% (8/18)(95% CI: 22.0 - 69.0) with geometric mean titers (GMTs) 72.1 and 4.6 respectively. The rates of seroconversion of immunofluorescent antibody by immunofluorescence antibody assay (IFA) were 28.6%, 83.3%, 75.0%, 53.1%, 22.6%, 10.0% and 55.0% before reinforcement, two weeks, one year, one year and a half years, two years, three years and five years after reinforcement. The rates of neutralizing antibody seroconversion by the Mcro-CPE method were found as 14.8%, 55.6%, 35.0%, 31.3%, 26.0%, 10.0% and 50.0% respectively. We found some antibody dependent immunization enhancement phenomenon among the inoculated population, but further observation was needed.


CONCLUSIONS
HFRS vaccine was immunologically effective and the duration of serous antibody last long.
Gong
Zhen-yu
ZY
Center for Disease Control and Prevention, Zhejiang Province, Hangzhou 310009, China.
Weng
Jing-qing
JQ
Zhao
Zhi-ya
ZY
Chen
Yu-tu
YT
Zhu
A-gen
AG
Fu
Gui-ming
GM
Fang
Chun-fu
CF
Zhu
Zhi-yong
ZY
Chen
En-fu
EF
Wang
Chui-zhang
CZ
Wang
Wei
W
Lei
Lin-hai
LH
Wang
Zhen
Z
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D002681:China / Q000453:epidemiology; D005455:Fluorescent Antibody Technique; D018063:Hantaan virus / Q000276:immunology*; D006480:Hemorrhagic Fever with Renal Syndrome / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D007115:Immunization Schedule; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008875:Middle Aged; D009500:Neutralization Tests; D014611:Vaccination; D014765:Viral Vaccines / Q000276:immunology*
D000914:Antibodies, Viral; D007074:Immunoglobulin G; D014765:Viral Vaccines